Health News Releases

August 29, 14:15

Novotech Earns Renewed Certification as an Employer of Choice for Gender Equality

Novotech, a global full-service clinical Contract Research Organization (CRO), proudly announces its continued recognition as a Workplace Gender Equality Agency (WGEA) Employer of Choice for Gender Eq

August 29, 14:00

HistoSonics™ Partners with Li Ka Shing Foundation to Launch First Histotripsy Programs in Hong Kong

HistoSonics, (www.histosonics.com), the developer and manufacturer of the Edison™ Histotripsy System, announced today the company’s initial partnership in Asia with Hong Kong University receiving thei

August 28, 16:50

Avantor Triumphs with Three Awards at Korea Biopharma Excellence Awards 2024

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences advanced technologies industries, has secured three prestigious awards at the estee

August 22, 14:05

PCI Pharma Services’ Bedford, New Hampshire Location Successfully Completes International Coalition of Medicines Regulatory Authorities Inspection

PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), has successfully completed the International Coalition of Medicines Regulatory Authorities (ICMR

August 21, 14:45

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced it has expanded its agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter

August 20, 15:55

Guard Medical Announces FDA 510(k) Clearance for Additional Large Sizes of Its Novel NPseal® NPWT Surgical Dressing, Unlocking the Orthopedic Market

Privately-held company Guard Medical Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.guard-medical.com%2F&esheet=54110779&newsitemid=20240819281623&lan=en-US&anchor=Guard+Me

August 16, 15:40

HistoSonics Announces Oversubscribed $102 Million Series D Financing to Scale Launch of Non-Invasive Histotripsy Platform

HistoSonics (https://histosonics.com/), the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced today the completion of an oversubscribed $102 million Ser

August 15, 10:25

Bio-Gene and Envu Collaborate to Evaluate Flavocide™ for Use in Public and Private Sector Mosquito Management

Bio-Gene Technology Limited (ASX:BGT or ‘Bio-Gene’), an Australian company developing the next generation of novel bio-insecticides, and Envu are evaluating Flavocide™ for use in professional pest man

August 14, 10:40

Freyr Recognized as a Leader in Everest Group PEAK Matrix® 2024

Freyr, a premier global Regulatory solutions and services provider, proudly announces its distinguished placement as a Leader in the esteemed Everest Group Life Sciences Regulatory and Medical Affairs

August 13, 16:19

Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis

Galderma today announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo n

August 13, 14:53

Brandnew Lab Concludes Successful Symposium for NUVOEN Launch

On August 13, Brandnew Lab (https://brandnewlab.co.kr) announced the successful launch of its highly anticipated clinical-use ampoule line, NUVOEN, at the symposium that took place on July 22 at the B

August 11, 09:45

Morinaga Milk Obtains the Registration of “New Food Ingredient” in China for use of its Probiotic Bifidobacterium infantis M-63 in Infant Foods

Morinaga Milk Industry Co., Ltd. (https://www.morinagamilk.co.jp/english/) (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium infantis M-

August 09, 15:35

Parse Biosciences Partners with Taiwan-based Prisma Biotech to Extend Reach in Asia

Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.parsebiosciences.com%2F&esheet=54104966&newsitemid=20240807623635&lan=en-US&anchor=Parse+Biosciences&index=1&md

August 09, 15:10

Nichi BRITE Beta glucan as an onco-nutrition supplement in pancreatic cancer; Encouraging clinical results reported by Chikamori Hospital, Japan.

Nichi BRITE Beta glucan administration resulted in enhancement of immunity followed by reduction in biomarkers of pancreatic cancer and that of its recurrence in patients undergoing surgical resection

August 09, 15:00

BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates

BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=54105663&newsitemid=20240807337131&lan=en-US&anchor=BeiGene&index=1&md5=66784fdcb48f17570d0bd05940b

August 08, 15:25

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54104396&newsitemid=20240806343138&lan=en-US&anchor=TSE%3A4

August 05, 14:39

Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology

Galderma today announced that it has signed a memorandum of understanding with L’Oréal to work towards a new research and development (R&D) collaboration in the form of a scientific partnership focuse

August 02, 09:40

In-Depth Report on Global Oesophageal Cancer Clinical Trials Now Available

Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, ha

August 01, 15:30

Boston Oncology and King Fahd Medical City (KFMC) Partner to Advance Localized Cell & Gene Therapy in Saudi Arabia

In a landmark initiative poised to transform healthcare in the Kingdom of Saudi Arabia, Boston Oncology and King Fahd Medical City (KFMC) have signed a Letter of Intent to collaborate on the localizat

August 01, 14:30

Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody/ADC therapeutics, announced that it has entered into an o

August 01, 14:00

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54099945&newsitemid=20240725145481&lan=en-US&anc

July 31, 11:40

Carestream Wins Renowned Award for Dental Films

We’re excited to announce Carestream recently received the Health Leaders Award in the Dental Category from Grupo Mídia in Brazil, a renowned international multimedia company. This distinguished aw

July 31, 10:45

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

Biogen Inc. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.biogen.com&esheet=54101572&newsitemid=20240730216833&lan=en-US&anchor=Biogen+Inc.&index=1&md5=4c98be33119620eca3992544

July 30, 15:15

Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s Shield™ blood test for colorectal cance

July 30, 14:32

Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

Galderma today announced that it has completed its European decentralized procedure (DCP), resulting in a positive decision for Relfydess™ (RelabotulinumtoxinA - previously referred to as QM1114). Rel

News by Region

News by Industry